Supplementary Table S2 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer

Supplementary Table S2 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer

<p>Supplementary Table S2. Results of single-sample gene set enrichment analysis (ssGSEA) of transcriptomic profiles from HCC-1428 and HCC-1428/LTED cells.</p>

Sábháilte in:

Sonraí bibleagrafaíochta
Príomhchruthaitheoir:	Nicole A. Traphagen (16677391) (author)
Rannpháirtithe:	Gary N. Schwartz (16005870) (author), Steven Tau (16677394) (author), Alyssa M. Roberts (16677397) (author), Amanda Jiang (15117790) (author), Sarah R. Hosford (16677400) (author), Jonathan D. Marotti (16005879) (author), Abigail E. Goen (16677403) (author), Bianca A. Romo (16677406) (author), Anneka L. Johnson (16677409) (author), Emily-Claire K. Duffy (16677412) (author), Eugene Demidenko (16005894) (author), Paul Heverly (16677415) (author), Yaron Mosesson (16677418) (author), Shannon M. Soucy (16005888) (author), Fred Kolling (16005891) (author), Todd W. Miller (16005897) (author)
Foilsithe / Cruthaithe:	2025
Ábhair:	Cancer Therapeutic Research and Development Breast Cancer Drug Mechanisms Cellular responses to anticancer drugs Drug Resistance Reversal of drug resistance
Clibeanna:	Cuir clib leis Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!

Míreanna comhchosúla

Supplementary Table S1 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
de réir: Nicole A. Traphagen (16677391)
Foilsithe / Cruthaithe: (2025)

Data file S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
de réir: Alex C.H. Liu (14961921)
Foilsithe / Cruthaithe: (2025)

Data file S2 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
de réir: Alex C.H. Liu (14961921)
Foilsithe / Cruthaithe: (2025)

Data file S3 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
de réir: Alex C.H. Liu (14961921)
Foilsithe / Cruthaithe: (2025)

Data file S4 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
de réir: Alex C.H. Liu (14961921)
Foilsithe / Cruthaithe: (2025)

Data file S5 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
de réir: Alex C.H. Liu (14961921)
Foilsithe / Cruthaithe: (2025)

Table S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
de réir: Alex C.H. Liu (14961921)
Foilsithe / Cruthaithe: (2025)

Supplementary Data from Pharmacological Targeting of Androgen Receptor Elicits Context-Specific Effects in Estrogen Receptor–Positive Breast Cancer
de réir: Lixuan Wei (14962431)
Foilsithe / Cruthaithe: (2025)

Figure S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
de réir: Dahihm Kim (16546203)
Foilsithe / Cruthaithe: (2025)

Figure S2 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
de réir: Dahihm Kim (16546203)
Foilsithe / Cruthaithe: (2025)

Figure S3 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
de réir: Dahihm Kim (16546203)
Foilsithe / Cruthaithe: (2025)

Figure S4 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
de réir: Dahihm Kim (16546203)
Foilsithe / Cruthaithe: (2025)

Figure S5 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
de réir: Dahihm Kim (16546203)
Foilsithe / Cruthaithe: (2025)

Table S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
de réir: Dahihm Kim (16546203)
Foilsithe / Cruthaithe: (2025)

Table S3 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
de réir: Dahihm Kim (16546203)
Foilsithe / Cruthaithe: (2025)

Supplementary Table 1 from Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers
de réir: Juliana Navarro-Yepes (17079059)
Foilsithe / Cruthaithe: (2025)

Table ST1 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
de réir: Ossia M. Eichhoff (14964145)
Foilsithe / Cruthaithe: (2025)

Table ST2 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
de réir: Ossia M. Eichhoff (14964145)
Foilsithe / Cruthaithe: (2025)

Table ST3 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
de réir: Ossia M. Eichhoff (14964145)
Foilsithe / Cruthaithe: (2025)

Table ST4 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
de réir: Ossia M. Eichhoff (14964145)
Foilsithe / Cruthaithe: (2025)

Table ST5 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
de réir: Ossia M. Eichhoff (14964145)
Foilsithe / Cruthaithe: (2025)

Table ST6 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
de réir: Ossia M. Eichhoff (14964145)
Foilsithe / Cruthaithe: (2025)

Table ST7 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
de réir: Ossia M. Eichhoff (14964145)
Foilsithe / Cruthaithe: (2025)

Table ST8 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
de réir: Ossia M. Eichhoff (14964145)
Foilsithe / Cruthaithe: (2025)

Table ST9 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
de réir: Ossia M. Eichhoff (14964145)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S1 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
de réir: Yufang Bao (15386826)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S2 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
de réir: Yufang Bao (15386826)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S3 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
de réir: Yufang Bao (15386826)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S4 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
de réir: Yufang Bao (15386826)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S5 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
de réir: Yufang Bao (15386826)
Foilsithe / Cruthaithe: (2025)

Supplementary Data 1 from Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer
de réir: Kavya Ramkumar (16474203)
Foilsithe / Cruthaithe: (2025)

Figure 1 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
de réir: Milana A. Bergamino (15038015)
Foilsithe / Cruthaithe: (2025)

Figure 2 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
de réir: Milana A. Bergamino (15038015)
Foilsithe / Cruthaithe: (2025)

Figure 3 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
de réir: Milana A. Bergamino (15038015)
Foilsithe / Cruthaithe: (2025)

Figure 4 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
de réir: Milana A. Bergamino (15038015)
Foilsithe / Cruthaithe: (2025)

Figure 5 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
de réir: Milana A. Bergamino (15038015)
Foilsithe / Cruthaithe: (2025)

Figure 6 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
de réir: Milana A. Bergamino (15038015)
Foilsithe / Cruthaithe: (2025)

Supplementary Movie S1 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
de réir: Fang Wei (15057172)
Foilsithe / Cruthaithe: (2025)

Supplementary Movie S2 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
de réir: Fang Wei (15057172)
Foilsithe / Cruthaithe: (2025)

Supplementary Movie S3 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
de réir: Fang Wei (15057172)
Foilsithe / Cruthaithe: (2025)

Cannot write session to /tmp/vufind_sessions/sess_93v3na6pdp1qg6pefjqll4du86